[go: up one dir, main page]

WO2010022055A3 - Inhibiteurs de canaux sodiques sensibles au potentiel - Google Patents

Inhibiteurs de canaux sodiques sensibles au potentiel Download PDF

Info

Publication number
WO2010022055A3
WO2010022055A3 PCT/US2009/054169 US2009054169W WO2010022055A3 WO 2010022055 A3 WO2010022055 A3 WO 2010022055A3 US 2009054169 W US2009054169 W US 2009054169W WO 2010022055 A3 WO2010022055 A3 WO 2010022055A3
Authority
WO
WIPO (PCT)
Prior art keywords
treatment
chronic pain
pain disorders
derivatives useful
ine derivatives
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2009/054169
Other languages
English (en)
Other versions
WO2010022055A2 (fr
Inventor
John L. Buchanan
Howard Bregman
Nagasree Chakka
Erin F. Dimauro
Bingfan Du
Hanh Nho Nguyen
Xiao Mei Zheng
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Inc
Original Assignee
Amgen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Inc filed Critical Amgen Inc
Publication of WO2010022055A2 publication Critical patent/WO2010022055A2/fr
Publication of WO2010022055A3 publication Critical patent/WO2010022055A3/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

La présente invention porte sur des composés qui sont des inhibiteurs de canal sodique sensible au potentiel (Nav), en particulier Nav 1.7 et sont particulièrement utiles pour le traitement de maladies pouvant être traitées par l'inhibition de ces canaux, en particulier, des troubles de douleur chronique. L'invention porte également sur des compositions pharmaceutiques contenant de tels composés et sur des procédés pour préparer de tels composés.
PCT/US2009/054169 2008-08-20 2009-08-18 Inhibiteurs de canaux sodiques sensibles au potentiel Ceased WO2010022055A2 (fr)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US18950108P 2008-08-20 2008-08-20
US61/189,501 2008-08-20
US19601208P 2008-10-14 2008-10-14
US61/196,012 2008-10-14

Publications (2)

Publication Number Publication Date
WO2010022055A2 WO2010022055A2 (fr) 2010-02-25
WO2010022055A3 true WO2010022055A3 (fr) 2010-06-17

Family

ID=41707632

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2009/054169 Ceased WO2010022055A2 (fr) 2008-08-20 2009-08-18 Inhibiteurs de canaux sodiques sensibles au potentiel

Country Status (1)

Country Link
WO (1) WO2010022055A2 (fr)

Families Citing this family (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011103196A1 (fr) * 2010-02-17 2011-08-25 Amgen Inc. Dérivés d'arylcarboxamide en tant qu'inhibiteurs de canal sodique pour le traitement de la douleur
ES2533990T3 (es) * 2010-02-24 2015-04-16 Research Triangle Institute Antagonistas de receptores opioides de arilpiperazina
US8871996B2 (en) 2010-06-09 2014-10-28 Regeneron Pharmaceuticals, Inc. Mice expressing human voltage-gated sodium channels
US8486647B2 (en) 2010-06-09 2013-07-16 Regeneron Pharmaceuticals, Inc. Neuropeptide release assay for sodium channels
CN102344407A (zh) * 2010-08-03 2012-02-08 艾琪康医药科技（上海）有限公司 一种3-氟哌啶衍生物及其制备方法
HRP20160094T1 (hr) * 2010-09-13 2016-02-26 Novartis Ag Triazin-oksadiazoli
EP2681193B1 (fr) 2011-03-02 2016-01-06 Lead Discovery Center GmbH Dérivés de pyridine disubstitués pharmaceutiquement actifs
CA2826464C (fr) 2011-03-02 2020-07-28 Lead Discovery Center Gmbh Derives de triazine disubstitues pharmaceutiquement actifs
CN102285969B (zh) * 2011-06-28 2013-06-19 山东大学 N-1-取代哌啶-4-芳胺类衍生物及其制备方法与应用
KR20140105445A (ko) 2011-10-31 2014-09-01 제논 파마슈티칼스 인크. 비아릴 에테르 술폰아미드 및 치료제로서의 그의 용도
BR112014010271A2 (pt) 2011-10-31 2017-04-18 Xenon Pharmaceuticals Inc compostos de benzenossulfonamida e seu uso como agentes terapêuticos
PE20150400A1 (es) 2012-05-22 2015-03-27 Genentech Inc Benzamidas n-sustituidas y su uso en el tratamiento del dolor
CA2878478A1 (fr) 2012-07-06 2014-01-09 Genentech, Inc. Benzamides n-substitues et leurs procedes d'utilisation
WO2014106238A1 (fr) * 2012-12-31 2014-07-03 Fang, Qun, Kevin Composés hétérocycliques et leurs procédés d'utilisation
US9040712B2 (en) * 2013-01-23 2015-05-26 Novartis Ag Thiadiazole analogs thereof and methods for treating SMN-deficiency-related-conditions
WO2014127116A1 (fr) 2013-02-13 2014-08-21 Novartis Ag Agents analgésiques oculaires topiques
JP6096370B2 (ja) 2013-03-14 2017-03-15 ジェネンテック， インコーポレイテッド 置換トリアゾロピリジンとその使用方法
JP6227112B2 (ja) 2013-03-15 2017-11-08 ジェネンテック， インコーポレイテッド 置換ベンゾオキサゾールとその使用方法
EP2970231A1 (fr) 2013-03-15 2016-01-20 Blueprint Medicines Corporation Dérivés de pipérazine et leur utilisation comme modulateurs de kit
GB2516303A (en) * 2013-07-18 2015-01-21 Redx Pharma Ltd Compounds
EP3039019B1 (fr) * 2013-08-26 2020-04-22 Purdue Pharma L.P. Dérivés d'azaspiro[4.5]décane et leur utilisation
US20160237071A1 (en) * 2013-10-02 2016-08-18 Nissan Chemical Industries, Ltd. T-type calcium channel inhibitor
EP3409674B1 (fr) 2013-10-17 2022-04-06 Blueprint Medicines Corporation Procédé pour préparer des compositions utiles pour traiter des troubles associés à un kit
WO2015058129A1 (fr) * 2013-10-17 2015-04-23 Blueprint Medicines Corporation Composés à utiliser pour traiter des troubles associés à l'enzyme kit
WO2015078374A1 (fr) 2013-11-27 2015-06-04 Genentech, Inc. Benzamides substitués et leurs méthodes d'utilisation
CN106103422B (zh) * 2014-02-12 2020-09-18 普渡制药公司 异喹啉衍生物及其用途
PE20161368A1 (es) * 2014-03-17 2016-12-25 Pfizer Inhibidores de diacilglicerol aciltranferasa 2
CN104016977B (zh) * 2014-06-13 2016-06-22 山东大学 一种取代噻二嗪二酮类衍生物及其制备方法与应用
CN106715418A (zh) 2014-07-07 2017-05-24 基因泰克公司 治疗化合物及其使用方法
WO2016022569A1 (fr) 2014-08-04 2016-02-11 Blueprint Medicines Corporation Composés utiles pour traiter des troubles associés à kit
AU2016268120A1 (en) 2015-05-22 2017-11-30 Genentech, Inc. Substituted benzamides and methods of use thereof
JP2018521076A (ja) 2015-07-24 2018-08-02 ブループリント メディシンズ コーポレイション Ｋｉｔ及びｐｄｇｆｒに関連する疾病を治療するのに有用な化合物
JP2018526371A (ja) 2015-08-27 2018-09-13 ジェネンテック， インコーポレイテッド 治療化合物及びその使用方法
WO2017058821A1 (fr) 2015-09-28 2017-04-06 Genentech, Inc. Composés thérapeutiques et leurs procédés d'utilisation
EP3380466A1 (fr) 2015-11-25 2018-10-03 Genentech, Inc. Benzamides substitués utiles en tant que bloqueurs de canaux sodiques
CN105837525B (zh) * 2016-03-25 2019-05-28 浙江工业大学 2,4-二胺-1,3,5-三嗪类化合物及其制备方法与应用
JP2019513714A (ja) 2016-03-30 2019-05-30 ジェネンテック， インコーポレイテッド 置換ベンズアミド及びその使用方法
CA3039853A1 (fr) 2016-10-17 2018-04-26 Genentech, Inc. Composes therapeutiques et leurs procedes d'utilisation
CN110099898B (zh) 2016-10-24 2023-07-25 优曼尼蒂治疗公司 化合物及其用途
FI3541784T3 (fi) 2016-11-18 2023-10-02 Integrative Res Laboratories Sweden Ab Uudet atsetidiinijohdannaiset, jotka ovat hyödyllisiä kortikaalisen katekoliamiini-neurotransmission modulaattoreina
EA037318B1 (ru) 2016-12-16 2021-03-11 Пфайзер Инк. Агонисты рецептора glp-1 и их применение
WO2018129403A1 (fr) 2017-01-06 2018-07-12 Yumanity Therapeutics Méthodes de traitement de troubles neurologiques
WO2018175707A1 (fr) 2017-03-24 2018-09-27 Genentech, Inc. Dérivés de 4-pipéridine-n-(pyrimidin-4-yl) chromane-7-sulfonamide en tant qu'inhibiteurs de canaux sodiques
CN106995380B (zh) * 2017-03-31 2018-12-28 九江善水科技股份有限公司 一种2-氨基-4-硝基苯酚的合成方法
WO2018183712A1 (fr) 2017-03-31 2018-10-04 Blueprint Medicines Corporation Composés de pyrrolo[1,2-b]pyridazine et compositions utiles pour traiter des troubles liés à kit et pdgfr
WO2019018795A1 (fr) * 2017-07-20 2019-01-24 Yumanity Therapeutics Composés et utilisations de ces composés
EP3700934A4 (fr) 2017-10-24 2021-10-27 Yumanity Therapeutics, Inc. Composés et utilisations de ces composés
WO2019165290A1 (fr) 2018-02-26 2019-08-29 Genentech, Inc. Composés de pyridine-sulfonamide et leur utilisation contre la douleur et les états associés
CN112312913B (zh) 2018-03-23 2024-03-08 詹森药业有限公司 化合物和其用途
WO2019191702A1 (fr) 2018-03-30 2019-10-03 F. Hoffmann-La Roche Ag Hydro-pyrido-azines substituées utilisées comme inhibiteurs du canal sodique
JP2021522253A (ja) 2018-04-25 2021-08-30 ユマニティ セラピューティクス，インコーポレーテッド 化合物及びその使用
TW202003490A (zh) 2018-05-22 2020-01-16 瑞士商赫孚孟拉羅股份公司 治療性化合物及其使用方法
AU2020212034A1 (en) 2019-01-24 2021-09-16 Janssen Pharmaceutica Nv Compounds and uses thereof
EP3856341B1 (fr) 2019-04-12 2023-09-06 Blueprint Medicines Corporation Formes cristallines de (s)-1-(4-fluorophényl)-1-(2-(4-(6-(1-méthyl-1h-pyrazol-4-yl))pyrrolo[2,1-f][1,2,4]triazin-4-yl)pipérazinyl)-pyrimidin-5-yl)éthan-1-amine et des procédés de fabrication
MX2021012469A (es) 2019-04-12 2022-01-18 Blueprint Medicines Corp Composiciones y metodos para el tratamiento de enfermedades mediadas por kit y pdgfra.
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
CN111057021B (zh) * 2019-12-11 2023-05-23 中国药科大学 均三嗪类化合物及其制备方法和用途
NZ788624A (en) * 2019-12-23 2025-08-29 Lg Chemical Ltd Novel amino aryl derivative useful as diacylglycerol acyltransferase 2 inhibitor and use thereof
ES2969310T3 (es) * 2019-12-23 2024-05-17 Lg Chemical Ltd Nuevo derivado de amida útil como inhibidor de diacilglicerol aciltransferasa 2, y uso del mismo
JPWO2023132208A1 (fr) * 2022-01-07 2023-07-13
WO2023229685A2 (fr) * 2022-02-24 2023-11-30 Microbiotix, Inc. Inhibiteurs à large spectre de cytomégalovirus
CN116178465A (zh) * 2023-03-06 2023-05-30 中国科学院成都生物研究所 含四元环的多酚类化合物及其应用
AU2024289298A1 (en) 2023-07-06 2026-01-15 Integrative Research Laboratories Sweden Ab Pharmaceutically acceptable salts of 3-(2,3-difluorophenoxy)azetidine and uses thereof
CN117384091B (zh) * 2023-12-08 2024-02-20 四川大学华西第二医院 一类酰胺衍生物、合成方法及用途

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083653A1 (fr) * 2001-04-11 2002-10-24 Amgen Inc. Derives d'acrylamide de triazinyle utilises comme inhibiteur de kinase
WO2002092576A1 (fr) * 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Derives de diaryluree utilisables en tant qu'agents anti-inflammatoires

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002083653A1 (fr) * 2001-04-11 2002-10-24 Amgen Inc. Derives d'acrylamide de triazinyle utilises comme inhibiteur de kinase
WO2002092576A1 (fr) * 2001-05-16 2002-11-21 Boehringer Ingelheim Pharmaceuticals, Inc. Derives de diaryluree utilisables en tant qu'agents anti-inflammatoires

Also Published As

Publication number Publication date
WO2010022055A2 (fr) 2010-02-25

Similar Documents

Publication Publication Date Title
WO2010022055A3 (fr) Inhibiteurs de canaux sodiques sensibles au potentiel
WO2009012242A3 (fr) Inhibiteurs des canaux sodiques
WO2007095124A3 (fr) Derives, compositions de benzazole et procedes d'utilisation en tant qu'inhibiteurs de la kinase aurora
IL196543A (en) Pyridazinone derivatives, pharmaceutical preparations containing them for use in the treatment of disorders
WO2006107451A3 (fr) Derives d'honokiol pour traiter les maladies proliferantes
WO2010017545A3 (fr) Composés de triazole qui modulent l'activité hsp90
WO2005110994A8 (fr) Derives de pyrazolyl uree substitues utiles dans le traitement du cancer
WO2008135826A3 (fr) Dérivés de la pyridine
WO2007021941A3 (fr) Inhibiteurs des canaux sodium sensibles au voltage
WO2008089307A3 (fr) Méthodes et compositions utilisés dans le traitement de la douleur, de l'inflammation et du cancer
MX346186B (es) Inhibidores de proteina cinasas.
WO2008147797A3 (fr) Modulateurs de canal ionique et leurs procédés d'utilisation
WO2005111039A3 (fr) Composés et procée pour l'inhibition de progression mitotique
WO2009076454A3 (fr) Compositions qui modulant le calcium intracellulaire
WO2008070016A3 (fr) Inhibiteurs de l'activité akt
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
WO2006135627A3 (fr) Inhibiteurs de l'activite akt
WO2009036996A3 (fr) Antagoniste de faible masse moléculaire du récepteur b1 de la bradykinine
WO2005046603A3 (fr) Composes pyridiniques
WO2008097924A3 (fr) Compositions pharmaceutiques comprenant des analogues du dextrométhorphane pour le traitement de troubles neurologiques
WO2008021038A3 (fr) Pyridobenzazépines et méthodes d'inhibition de la progression mitotique
WO2010011772A3 (fr) Inhibiteurs de la pyrazolopyridine kinase tricyclique
WO2007109279A3 (fr) Composes de tetrahydropyridothienopyrimidine et leurs procedes d'utilisation
WO2008013987A3 (fr) Pipérazinylméthylquinazolinones et azépanylméthylquinazolinones à substitution n-alkyle
WO2010042925A3 (fr) Compositions et méthodes pour traiter les troubles liés à la consommation d'alcool, la douleur et d'autres maladies

Legal Events

Date Code Title Description
NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 09791616

Country of ref document: EP

Kind code of ref document: A2